Compounds > methotrexate
Page last updated: 2024-08-25

methotrexate and Thrombotic Microangiopathies

methotrexate has been researched along with Thrombotic Microangiopathies in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Girndt, M; Lübbert, C; Pliquett, RU; Schäfer, C1
Garcia, H; Grangé, S; Rafat, C1
Alberca, I; Caballero, D; Cabrero-Calvo, M; Del Cañizo, MC; Díez-Campelo, M; González-Porras, JR; Guerrero, C; Labrador, J; López-Corral, L; López-Godino, O; Pérez-López, E; Pérez-López, R; Pérez-Simón, JA; Sánchez-Guijo, F; Vázquez, L1
Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S1
Abdelqader, S; Abonour, R; Baute, J; Cornetta, K; Farag, SS; Fausel, CA; Kalsekar, I; Kiel, PJ; Nelson, RP; Robertson, MJ; Rosenbeck, LL; Schwartz, J; Srivastava, S; Sullivan, CK; Vargo, C; Wood, L1

Other Studies

5 other study(ies) available for methotrexate and Thrombotic Microangiopathies

ArticleYear
Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report.
    Journal of medical case reports, 2020, Feb-05, Volume: 14, Issue:1

    Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Leflunomide; Methotrexate; Middle Aged; Thrombotic Microangiopathies

2020
[Acute renal failure and cancer treatment].
    La Revue du praticien, 2021, Volume: 71, Issue:2

    Topics: Acute Kidney Injury; Humans; Kidney; Methotrexate; Neoplasms; Thrombotic Microangiopathies

2021
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Bone marrow transplantation, 2014, Volume: 49, Issue:5

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Sirolimus; Tacrolimus; Thrombotic Microangiopathies; Transplantation, Homologous; Young Adult

2014
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Pediatric nephrology (Berlin, Germany), 2016, Volume: 31, Issue:6

    Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment

2016
Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6

    Topics: Adult; Antilymphocyte Serum; Calcineurin Inhibitors; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Retrospective Studies; Risk Factors; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Transplantation Conditioning; Transplantation, Homologous; Young Adult

2011